Management of Funguria
Most patients with asymptomatic funguria should NOT be treated with antifungal agents unless they are neutropenic, very low-birth-weight infants (<1500 g), or undergoing urologic procedures 1. The single most important intervention is removing the indwelling bladder catheter if present.
Risk Stratification: Who Needs Treatment?
The IDSA 2016 guidelines provide clear stratification based on dissemination risk 1:
High-Risk Patients Requiring Treatment:
- Neutropenic patients → Treat as candidemia
- Very low-birth-weight infants (<1500 g) → Treat as candidemia
- Patients undergoing urologic procedures → Prophylactic treatment several days before and after
- Symptomatic cystitis or pyelonephritis → Targeted antifungal therapy
Low-Risk Patients (No Treatment Needed):
- Asymptomatic funguria with indwelling catheter
- Asymptomatic funguria without risk factors
- Immunocompetent hospitalized patients without planned procedures
This approach is supported by research showing that treatment of asymptomatic funguria does not impact mortality or morbidity 2. Funguria often represents colonization rather than true infection, and spontaneous resolution occurs frequently after catheter removal 3, 4.
Treatment Algorithm by Clinical Scenario
1. Asymptomatic Funguria (Most Common)
Primary intervention: Remove indwelling bladder catheter 1
No antifungal therapy needed unless high-risk features present 1
2. Symptomatic Candida Cystitis
First-line: Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks for fluconazole-susceptible organisms 1
For fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days, OR
- Oral flucytosine 25 mg/kg four times daily for 7–10 days 1
For C. krusei:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1
Critical adjunct: Remove indwelling bladder catheter 1
Alternative for resistant species: Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be considered, though evidence is weak 1. Note that bladder irrigation has questionable therapeutic value and should not replace systemic therapy when indicated 5.
Recent data suggest shorter durations may be adequate—a 2025 study found no difference in clinical success between 7 days versus 14 days of fluconazole 6, though guidelines still recommend 2 weeks.
3. Candida Pyelonephritis
First-line: Oral fluconazole 200–400 mg (3–6 mg/kg) daily for 2 weeks for fluconazole-susceptible organisms 1
For fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days with or without oral flucytosine 25 mg/kg four times daily 1
- Alternative: Flucytosine monotherapy 25 mg/kg four times daily for 2 weeks (weaker recommendation) 1
For C. krusei:
- Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1
Critical interventions:
4. Periprocedural Prophylaxis
For patients undergoing urologic procedures with funguria:
Oral fluconazole 400 mg (6 mg/kg) daily OR amphotericin B deoxycholate 0.3–0.6 mg/kg daily for several days before and after the procedure 1
5. Fungal Balls/Bezoars
Surgical intervention strongly recommended 1
Plus antifungal therapy as outlined for cystitis or pyelonephritis 1
If nephrostomy tubes present: Irrigation with amphotericin B deoxycholate 25–50 mg in 200–500 mL sterile water 1
Species-Specific Considerations
Fluconazole-susceptible species (most C. albicans): Fluconazole is preferred due to excellent urinary concentration, oral bioavailability, and tolerability 1, 4
C. glabrata: Often fluconazole-resistant; requires amphotericin B or flucytosine 1
C. krusei: Intrinsically fluconazole-resistant; requires amphotericin B 1
Common Pitfalls to Avoid
Treating asymptomatic funguria in catheterized patients without risk factors → This does not improve outcomes and promotes resistance 2
Relying solely on bladder irrigation → Has questionable efficacy and should not replace systemic therapy when indicated 5
Failing to remove/replace urinary catheters → This is the most important intervention and often leads to spontaneous resolution 1, 3, 4
Not obtaining species identification and susceptibility testing → C. glabrata and C. krusei require different management than C. albicans
Treating colonization as infection → Most funguria represents colonization; symptoms and host factors determine need for treatment 3, 4, 2
Key Management Principles
- Source control is paramount: Remove catheters, relieve obstruction, control diabetes 1, 4
- Risk stratification drives treatment decisions: Only high-risk or symptomatic patients benefit from antifungals 1
- Fluconazole is first-line when susceptible: Excellent urinary penetration and oral availability 1
- Duration is typically 2 weeks for cystitis/pyelonephritis, though emerging data suggest shorter courses may suffice 6
- Echinocandins have poor urinary penetration and should not be used for isolated urinary tract infections 1